Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Northwestern University
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02993159
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Seema Khan, MD, Seema A. Khan, MD, Melissa L. Pilewskie, MD, Joseph M. Guenther, MD, Stephen R. Grobmyer, MD, Eun-Sil (Shelley) Hwang, MD, Amy C. Degnim, MD

See list of participating sites